Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases
1. Auflage
Erschienen am 13. August 2024
231 Seiten
978-981-5238-75-4 (ISBN)
Beschreibung
No detailed description available for "Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases".
Alle Preise
Weitere Details
Weitere Ausgaben
Andere Ausgaben
Anuradha Mishra | Preeti Bajpai | Tarique Mahmood Ansari
Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases
Buch
07/2024
Bentham Science Publishers
88,55 €
Versand in 3-4 Wochen
Inhalt
- Cover
- Title
- Copyright
- End User License Agreement
- CONTENTS
- FOREWORD
- PREFACE
- INTRODUCTION
- List of Contributors
- A Systematic Review of Neurodegenerative Diseases: Etiology, Clinical Symptoms, Pathogenesis, and Future Developments
- Satya Prakash Singh1,*, Deepti Dwivedi2, Rabiya Ahsan3, Ankur Srivastava4 and Ajay Kumar Shukla4
- INTRODUCTION
- Parkinson's Disease
- Huntington's Disease
- Alzheimer's Disorders
- Amyotrophic Lateral Sclerosis (ALS)
- Symptoms of Neurodegenerative Diseases
- Neurodegeneration: Etiologies
- Ageing: Relevant to the Growth of Neurodegenerative Disorders
- Neurodegenerative Disorders Caused by Mitochondrial Dysfunction
- Recent Treatments of Cognitive Impairments
- Pathologies that Mitochondrial DNA Mutations may Cause
- CONCLUSION AND FUTURE DEVELOPMENTS
- ABBREVIATIONS
- REFERENCES
- Neuro-inflammatory Responses in Alzheimer's v/s Parkinson's Diseases
- Amrutha K.1 and Sarika Singh1,2,*
- INTRODUCTION
- INFLAMMATORY RESPONSES IN ALZHEIMER'S DISEASE
- INFLAMMATORY RESPONSES IN PARKINSON'S DISEASE
- APPLICATION OF NEUROINFLAMMATORY RESPONSES FOR DISEASE DIAGNOSIS
- TUMOR NECROSIS FACTOR-? (TNF-?)
- INTERLEUKIN-1? (IL-1?)
- NITRIC OXIDE (NO)
- CYCLOOXYGENASE- 2 (COX-2)
- INTERFERONS (IFNS)
- ASTROCYTES
- UTILIZATION OF NEUROINFLAMMATORY RESPONSES FOR THERAPEUTICS
- CONCLUSION
- REFERENCES
- Immunopathogenesis of Alzheimer's disease, Parkinson's Disease, and other Neurodegenerative Diseases
- Sunil Kumar1, Ajay Kumar Shukla2, Vimal Kumar Yadav2, Ankur Srivastava2, Deepti Dwivedi3 and Satya Prakash Singh1,4,*
- INTRODUCTION
- Worldwide Data of AD
- Pathophysiology of Immunopathogenic Neurodegenerative Disease Hypotheses
- AMYLOID-? HYPOTHESIS
- Protein Aggregation
- CHOLINERGIC HYPOTHESIS
- METAL HYPOTHESIS
- TAU PROTEIN HYPOTHESIS
- Toxic Oligomer' Hypothesis
- Protein Homeostasis Hypothesis (Protein (Mis) Folding)
- Dissents and Molecular Chaperones
- Protein Misfolding and Endoplasmic Reticulum Stress
- Unfolded Protein Response (UPR)
- Interaction of Proteins
- Autophagy and Neurodegeneration
- UPS in Neurodegenerative Disorders
- Aggresomes
- OXIDATIVE STRESS
- Metals and Oxidative Stress
- Oxidative Stress in Other Neurodegenerative Disorders
- IMPAIRED MITOCHONDRIAL DYSFUNCTION HYPOTHESIS
- FRAGMENTATION OF NEURONAL GOLGI HYPOTHESIS
- DISRUPTION OF CELLULAR/AXONAL TRANSPORT DYSREGU- LATION HYPOTHESIS
- Axonal Transport in Other Neurodegenerative Diseases
- DYSFUNCTION OF NEUROTROPHINS HYPOTHESIS
- NEUROINFLAMMATORY HYPOTHESIS
- THE ROLE OF CHEMOKINES IN NEURODEGENERATIVE DISEASES (NDD) HYPOTHESIS
- CCL2 (Monocyte Chemoattractant Protein
- Human Macrophage Inflammatory Protein 1a (CCL3)
- CXCL8 (Interleukin 8)
- CXCL12 (Stromal Cell-Derived Factor 1)
- CX3CL1 (Fractalkine)
- MULTIFACETED NEURONAL DEATH HYPOTHESIS
- Cell Death Cascades in NDDs
- THE IMMUNOPATHOGENESIS OF GUT MICROBIOTA HYPOTHESIS
- Gut Microbiota Responsible for Neurodegenerative Diseases
- Gut Microbiota Impact on Immune System and Neuroinflammation
- Gut Microbiota Impact on Activities
- NEUROTRANSMITTERS HYPOTHESIS
- NEW INSIGHTS PATHOGENESIS
- Gamma Oscillations Ameliorate Pathology and Cognitive Impairment in AD
- Aß and Tau Prions Spread Through the Brains of AD Patients
- Aß Interact with Hippocampal Ghrelin/GHSR1a Signaling in AD
- Aß Constrict Cerebral Capillaries in AD Pathology
- CONCLUSION
- AUTHOR CONTRIBUTIONS
- REFERENCES:
- Immunobiology and Immunotherapies in Huntington's Disease
- Arttatrana Pal1,*, Golden Kumari1 and Sonu Kumar1
- INTRODUCTION
- IMMUNE SYSTEM AND BRAIN
- Immune System and HD brain
- Mechanisms of Neurodegeneration in HD
- Clinical Features in HD
- Immune Complement System in HD
- Pathways of the Complement System and Cytokines in HD
- Neuro-inflammation and Neurodegeneration in HD
- ROLE OF INNATE AND ADAPTIVE IMMUNE RESPONSES IN HD
- Role of Microglia
- mHTT and Inflammation
- Monocytes and Macrophages in HD
- Complement System
- IL-6
- IL-1ß
- TNF-a
- TLRs
- Mast Cells
- ROLE OF ADAPTIVE IMMUNE RESPONSES IN HD
- Dendritic Cells
- T Cells
- IL-4
- Immune Treatment for HD
- IMMUNOMODULATORY DRUGS FOR HD
- Drugs for Chorea in HD
- Tetrabenazine
- Deutetrabenazine
- Dopamine Antagonists
- Anti-glutamatergic
- Antipsychotic Medication
- More Drugs for HD
- Laquinimod
- Anti-semaphorin 4D
- Anti-TNF-a Therapy
- Immunotherapies for mHTT
- Antibody-based Therapy for HD
- Indirect Therapies Helpful for HD Subjects Along with Immunotherapy
- Speech Therapy
- Physical Therapy and Establishing a Routine Activity
- Supplements for HD
- Future Perspectives
- CONCLUSION
- REFERENCES
- Introduction to Gut Microbiota and their Effects on Various Brain Disorders
- Afreen Usmani1,* and Anuradha Mishra2
- INTRODUCTION
- EFFECTS OF INTESTINAL MICROBIOME-BASED THERAPIES ON NEURODEGENERATIVE DISEASES
- Alzheimer's Disease (AD)
- Parkinson's Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Neurodegenerative Diseases and Short Chain Fatty acids (SCFAs)
- CONCLUSION
- Future Perspective
- ACKNOWLEDGEMENT
- REFERENCES
- Interplay Between Gut-microbiota and Neurodegeneration
- Sumel Ashique1,*, Radheshyam Pal1, Shubneesh Kumar2, Bharti Verma3, Nitish Kumar3, Ivan Kahwa4, Arshad Farid5, Neeraj Mishra6,*, Prashant Kumar7 and Farzad Taghizadeh-Hesary8,9
- INTRODUCTION
- GUT MICROBIOTA
- Gut Microbiota and Neurodegenerative Disease: A Correlation
- BRAIN AND GUT MICROBIOTA COMMUNICATIONS
- Gut-Brain Axis
- Blood-Brain Barrier and Molecules Derived from the Gut
- Central Nervous System Modifications
- Modification of Immune System
- A NEW PARTICIPANT IN NEURODEGENERATIVE DISEASES: GUT MICROBIOTA: CNS HOMEOSTASIS
- Microbiome's Role in Alzheimer's Disease (AD)
- Microbiome's Role in Parkinson's Disease
- Microbiome's Role in Huntington's Disease
- Microbiota Implicates Internal Factor - Influence on Multiple Sclerosis
- Gut Microbiota and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
- Gut Microbiota and Various Different Forms of Dementia
- GUT MICROBIOME, OXIDATIVE STRESS, AND NEURODE- GENERATION
- GUT MICROBIOME IN NEUROPROTECTION
- Gut Microbiome Metabolites for Neuroprotection with their Cell-specific Responses
- Gut Microbiome Interaction with Specific Host Molecules
- Interaction between Dietary Molecules and Gut Microbiome
- ASSESSING THE IMPACT OF GUT MICROBIOTA ON BRAIN NEURODEGENERATION USING EXPERIMENTAL MODELS
- Systems for Continual Gut Microbiota Culture
- Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
- TNO Gastro-Intestinal Model (TIM)
- Dynamic Gastro-Intestinal Simulator (SIMGI)
- CONCLUSION
- ACKNOWLEDGMENT
- REFERENCES
- Epigenetic Regulation of Microglia: Plausible Mechanism and Interventional Approaches in Neurodegeneration
- Sameen Shafi1, Hafizur Rahman Khan2 and Preeti Bajpai1,*
- INTRODUCTION
- Origin of Microglia
- Microglial Polarization Phenotype
- MICROGLIAL FUNCTIONS
- Maintenance of Synapses
- Synaptic Pruning
- Regulating Nerve Network
- Neurotransmitter Receptors on Microglia
- EPIGENETIC REGULATION OF MICROGLIA
- Histone Acetylation
- Histone Methylation
- DNA Methylation
- Epigenetic Crosstalk
- CONCLUSION
- REFERENCES
- Epigenetics as Diagnostic and Therapeutic Tool in Neurodegenerative Disorders
- Rufaida Wasim1,*, Tarique Mahmood1, Farogh Ahsan1, Aditya Singh1 and Asad Ahmad1
- INTRODUCTION
- EARLY DIAGNOSIS AND TREATMENT
- NEURODEGENERATIVE DISORDERS AND EPIGENETIC ALTE- RATION
- POTENTIAL EPIGENETIC THERAPEUTIC INTERVENTION TARGETS
- Inhibitors of DNA Methylation and DNA Methyltransferases (DNMT)
- Histone Acetylation and Histone Deacetylases (HDAC) Inhibitors
- NEURODEGENERATIVE DISORDERS TREATMENT
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- CONCLUSION
- ACKNOWLEDGMENT
- REFERENCES
- Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
- Suneela Dhaneshwar1,*, Mohammad Aadil Bhat2, Anuradha Singh2 and Supriya Roy2
- INTRODUCTION
- Drug Repurposing
- ALZHEIMER'S DISEASE (AD)
- DRUG REPURPOSING FOR AD
- Anti-cancer Agents
- Epidermal Growth Factor Receptor Inhibitors (EGFRI)
- Tyrosine Kinase Inhibitors
- Retinoid X Receptor (RXR) Agonists
- Miscellaneous Drugs
- Antidiabetic Drugs
- Hypoglycaemic Agents
- Anti-hyperglycaemic Drugs
- Antihypertensive Drugs
- Antiepileptic Drugs
- Phosphodiesterase-5 Inhibitors
- PARKINSON'S DISEASE (PD)
- Drug Repurposing for PD
- Exenatide
- Nilotinib
- Terazosin
- Simvastatin
- Ursodeoxycholic Acid
- ISRADIPINE
- HUNTINGTON'S DISEASE (HD)
- Drug Repurposing for HD
- Tetrabenazine
- Olanzapine
- Memantine
- Risperidone
- Quetiapine
- Amantadine
- Statins
- FRIEDREICH ATAXIA (FRDA)
- Drug Repurposing
- Dyclonine
- Diazoxide
- Dimethyl Fumarate
- Etravirine
- PPAR-? Agonist
- SPINAL MUSCULAR ATROPHY (SMA)
- Drug Repurposing for SMA
- Riluzole and Rasalgiline
- Masitinib
- Amifampridine
- Celecoxib and Hydroxyurea
- Salbutamol
- AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- Drug Repurposing for ALS
- Ezogabine
- Memantine
- Masitinib
- Rasagiline
- Mexiletine
- Ibudilast
- Triumeq
- CONCLUSION
- REFERENCES
- Subject Index
- Back Cover
